EC approves Horizon's Uplizna for neuromyelitis optica spectrum disorder - Pharmaceutical Technology
5/3/2022 12:00:00 AM3 years 10 months ago
by Vishnu Priyan
by Vishnu Priyan
The European Commission (EC) has granted approval for Horizon Therapeutics’ Uplizna (inebilizumab) as monotherapy to treat neuromyelitis optica spectrum disorder (NMOSD) in adults. The treat
The European Commission (EC) has granted approval for Horizon Therapeutics Uplizna (inebilizumab) as monotherapy to treat neuromyelitis optica spectrum disorder (NMOSD) in adults. The treatment is i… [+2131 chars]
full article...